How do I buy Equillium, Inc. Common Stock (EQ) stock?

Buying Equillium, Inc. Common Stock (EQ) stock is now easy and instant through the Gotrade app. Download the Gotrade app from the App Store or Google Play. Create an account and complete KYC. Make a deposit. Search for the code "EQ", then tap "Trade". Tap the "Buy" button. Enter the amount you want to buy. You have two options: Buy EQ by number of shares. Buy fractional shares in dollars, starting from $1. Swipe up to confirm your order, and you're done!

What is the minimum investment for EQ on Gotrade?

On Gotrade, you don't have to buy a full lot. With fractional shares, you can start investing in Equillium, Inc. Common Stock from just $1. A small budget shouldn't stop you from building a US stock portfolio.

Does Equillium, Inc. Common Stock (EQ) pay dividends?

At the moment, Equillium, Inc. Common Stock (EQ) does not pay dividends because it focuses on reinvesting profits for company growth (a growth stock). However, you can still potentially earn profit from share price increases (capital gains). Track EQ's performance via the price chart in the Gotrade app.

Is buying EQ on Gotrade safe and legal?

Gotrade is the trading name of Gotrade Securities Inc., which is registered with and supervised by the Labuan Financial Services Authority (LFSA).

What are the market hours to buy EQ?

You can place orders 24/7. Transactions will be executed when the US market (NYSE/NASDAQ) is open, from 9:30 PM to 4:00 AM WIB. Gotrade also provides access to pre-market and after-hours trading, so you have more flexibility and aren't limited to regular working hours. Market hours may change due to daylight saving time and holidays. In Gotrade, you can see the market status (open/closed) directly in the app.

How do I tell if EQ is expensive or cheap?

There's no single perfect answer, but common approaches include: Compare valuation (e.g., P/E, P/S) against historical averages or competitors. Review revenue and earnings growth. Check margins and cash flow. Evaluate business outlook and the company's position within its industry. You can combine fundamental analysis with an investing strategy that matches your risk profile. All of the information above can be viewed directly in the Gotrade app.

Equillium, Inc. Common Stock (EQ) Stock Price: Oct 9 Close $1.41

Latest news

MarketBeat

Equillium Eyes Q4 Phase I Start for Ulcerative Colitis Drug EQ504

NeutralEQSeptember 27, 2026

MarketBeatNeutral

Equillium Eyes Q4 Phase I Start for Ulcerative Colitis Drug EQ504

EQ

Reuters

EQ Resources to take 10% stake in Nevada tungsten project JV with Elmet, Blue Moon

EQSeptember 15, 2026

Reuters

EQ Resources to take 10% stake in Nevada tungsten project JV with Elmet, Blue Moon

EQ

MarketBeat

News tone: automated (AI) classification of the article's content, not a price prediction.

About Equillium, Inc. Common Stock

Equillium Inc is a clinical-stage biotechnology company engaged in developing novel therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. The company intends to commercialize its product candidates either independently or through partnerships, or otherwise monetize its pipeline through strategic transactions. Itolizumab (EQ001), a clinical-stage product candidate, is an anti-CD6 immune-modifying monoclonal antibody, or mAb, that selectively targets the CD6-ALCAM signaling pathway to downregulate pathogenic T effector cells while preserving T regulatory cells critical for maintaining a balanced immune response. The company's other clinical-stage and pre-clinical-stage candidates include EQ101 and EQ302.

SectorHealthcare

IndustryBiotechnology

Employees14

CEOMr. Bruce Steel

IPO DateOct 12, 2018

HeadquartersLa Jolla, CA

Key Executives

Name	Title	Year Born
Mr. Bruce Steel	Co-Founder, CEO & Director	1966
Dr. Stephen Connelly Ph.D.	Chief Scientific Officer & President	1981
Ms. Christine Zedelmayer M.B.A., P.M.P.	Senior VP & COO	1970
Ms. Penny Tom CPA	Senior VP of Finance & Principal Accounting Officer	—
Mr. Michael Moore	Vice President of Investor Relations & Corporate Communications	—
Ms. Snehal Naik Ph.D.	Chief Development Officer	—
Dr. Lisette Acevedo	Vice President of Clinical Development	—

Fundamentals

Valuation

Market cap$89.41M

Price-to-sales ratio28.55

Price-to-book value1.63

Price-earnings ratio-5.10

Return on Equity-41.00%

Return on Assets-38.00%

Earnings Per Share

Earnings Per Share$-0.14

Income Statement

Average volume746,843

EBITDA$-17.91M

1 year high (52w)$3.54

1 year low (52w)$0.76

Dividend

Dividend amount$0.00

Dividend yield0.00%

Source: third-party data provider, as of October 12, 2026

Technical indicators

RSI 14: 29.20
MACD 12/26/9: -0.21
EMA 9 of MACD: -0.19
MACD histogram: -0.01
SMA 50: $2.04; Price below SMA 50
EMA 50: $1.97; Price below EMA 50
SMA 200: $2.08; Price below SMA 200
EMA 200: $1.91; Price below EMA 200

Calculated by Gotrade from daily closing prices, as of October 9, 2026. Technical data, not a recommendation.

Analyst views

1 analyst rating

Third-party analyst opinion, not a recommendation from Gotrade.

Analyst consensus:Buy

100% Buy

0% Hold

0% Sell

Analyst price target

Low: $12.00
Average: $12.00
High: $12.00

Roth Capital

Adam Walsh

Buy

Target price

$12.00

Seasonality

Monthly price change (%)

	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec
2026			+1.5	+0.0	+39.4	+3.9	-27.6	+3.2	-26.2	-8.4

Compare stocks

EQ

Buy EQ

Market cap

$89.41M

-

Price / Earnings ratio

-5.10

-

Price / Sales ratio

28.55

-

Dividend yield

0.00%

-

Average volume

746,843

-

Earnings per share

$-0.14

-

Equillium, Inc. Common Stock (EQ) Stock

Fundamentals

Compare with EQ

Recent news

Equillium Eyes Q4 Phase I Start for Ulcerative Colitis Drug EQ504

Equillium Eyes Q4 Phase I Start for Ulcerative Colitis Drug EQ504

EQ Resources to take 10% stake in Nevada tungsten project JV with Elmet, Blue Moon

EQ Resources to take 10% stake in Nevada tungsten project JV with Elmet, Blue Moon

Equillium Links AhR Activation to miR-124 as EQ504 Heads Toward Phase 1

Equillium Links AhR Activation to miR-124 as EQ504 Heads Toward Phase 1

These Were the 5 Top-Performing Stocks in the Nasdaq Composite in August 2025

These Were the 5 Top-Performing Stocks in the Nasdaq Composite in August 2025

Technical indicators

Analyst ratings

Financials

Performance

Debt & Balance Sheet

Revenue to Profit

Earnings

Latest news

Equillium Eyes Q4 Phase I Start for Ulcerative Colitis Drug EQ504

Equillium Eyes Q4 Phase I Start for Ulcerative Colitis Drug EQ504

EQ Resources to take 10% stake in Nevada tungsten project JV with Elmet, Blue Moon

EQ Resources to take 10% stake in Nevada tungsten project JV with Elmet, Blue Moon

Equillium Links AhR Activation to miR-124 as EQ504 Heads Toward Phase 1

Equillium Links AhR Activation to miR-124 as EQ504 Heads Toward Phase 1

These Were the 5 Top-Performing Stocks in the Nasdaq Composite in August 2025

These Were the 5 Top-Performing Stocks in the Nasdaq Composite in August 2025

5 Top-Ranked Stocks That Have More Than Doubled Year to Date

5 Top-Ranked Stocks That Have More Than Doubled Year to Date

About Equillium, Inc. Common Stock

Key Executives

Fundamentals

Valuation

Earnings Per Share

Income Statement

Dividend

Technical indicators

Analyst views

Seasonality

Compare stocks

Market cap

Price / Earnings ratio

Price / Sales ratio

Dividend yield

Average volume

Earnings per share

Stocks in the same sector

FAQ

Trading Lebih Cepat. Lebih Mudah. Lebih Cerdas.

#ReadyGoTrade